TRVNTrevena
About Trevena
Trevena (NASDAQ:TRVN) specializes in developing innovative treatments targeting central nervous system (CNS) disorders, aiming to provide novel therapies for conditions with significant unmet medical needs. Its diverse portfolio includes several in-development drugs designed to tackle pain management, acute heart failure, and other critical areas. A notable project is OLINVYK, a U.S. FDA-approved intravenous opioid designed for acute pain management in adult patients, exemplifying Trevena's commitment to addressing challenging health care issues. With a focus on leveraging its proprietary platform to discover and advance new therapeutics, Trevena's objective remains firmly on enhancing patient care through scientific innovation and strategic partnerships.
What is TRVN known for?
Snapshot
Public US
Ownership
2007
Year founded
35
Employees
Pennsylvania, United States
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Trevena
- OLINVYK (oliceridine) is an opioid agonist for the management of moderate to severe acute pain in adults for whom an intravenous opioid is warranted.
- TRV027 is a novel AT1 receptor selective agonist aimed at treating acute lung injury including that caused by COVID-19.
- TRV734 is a biased ligand targeting the mu-opioid receptor, developed for the potential treatment of pain without the side effects of traditional opioids.
- TRV250 is a delta receptor agonist for the treatment of refractory migraine, designed to offer pain relief without the risk of addiction.
- The company's early-stage research focuses on discovering and developing novel biased ligands targeting G protein-coupled receptors (GPCRs) to address unmet medical needs in CNS disorders.
- They are exploring the use of their proprietary platform technology to develop S1P receptor modulators for the treatment of autoimmune and inflammatory diseases.
equipe executiva do Trevena
- Ms. Carrie L. BourdowPresident, CEO & Chairman
- Dr. Mark A. Demitrack M.D.Senior VP & Chief Medical Officer
- Dr. Howard A. Rockman M.D.Scientific Founder, Consultant and Member of Scientific Advisory Board
- Ms. Katrine SuttonPrincipal Financial Officer & principal accounting officer
- Mr. Robert T. YoderSenior VP, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer
- Mr. Michael CatalanoVice President of Marketing